tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Rallybio receives $12.5M equity milestone payment from Recursion Pharmaceuticals
PremiumThe FlyRallybio receives $12.5M equity milestone payment from Recursion Pharmaceuticals
4M ago
Rallybio Granted Extension for Nasdaq Compliance
Premium
Company Announcements
Rallybio Granted Extension for Nasdaq Compliance
5M ago
Rallybio Corporation Reports Q2 2025 Financial Results
Premium
Company Announcements
Rallybio Corporation Reports Q2 2025 Financial Results
5M ago
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
PremiumThe FlyRallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
6M ago
Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102
Premium
The Fly
Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102
6M ago
Rallybio Finalizes Employment Agreement with CMO
Premium
Company Announcements
Rallybio Finalizes Employment Agreement with CMO
7M ago
Rallybio Reports Q1 2025 Financial Results and Strategic Updates
PremiumCompany AnnouncementsRallybio Reports Q1 2025 Financial Results and Strategic Updates
8M ago
Rallybio reports Q1 EPS (21c), consensus (28c)
Premium
The Fly
Rallybio reports Q1 EPS (21c), consensus (28c)
8M ago
Rallybio downgraded to Hold from Buy at JonesResearch
Premium
The Fly
Rallybio downgraded to Hold from Buy at JonesResearch
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100